Skip to main content
Smart Investors Daily
ResMed Inc. logo

NYSE · RMD

ResMed Inc.

Healthcare · Medical - Instruments & Supplies

$236.88

Down-$5.73 (-2.36%)

Updated Nov 20, 2026, 2:01 AM

SID Score

6.4/10

Composite research score

Smart Money

58/100

Neutral

Market cap
36.98B
P/E ratio
25.71
Dividend yield
0.95%
52-week range
$180.27 – $277.67
Volume
1.14M
Avg. volume
1.04M

Price performance · RMD

RMD price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 19, 2026

RMD closed at $236.88 after 21 trading sessions, down 6.39% for the selected period.

Last close
$236.88
Period change
-6.39%
Period low
$227.08
Period high
$253.20
Daily close
View OHLC price history
RMD OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 19, 2026$242.48$242.99$236.02$236.881.14M
Nov 18, 2026$236.38$246.14$236.14$242.611.24M
Nov 17, 2026$237.00$241.22$233.4159$237.851.48M
Nov 16, 2026$240.00$243.00$238.10$238.191.05M
Nov 13, 2026$241.20$241.855$239.13$239.53853.19K
Nov 12, 2026$238.78$243.45$237.8309$238.891.09M
Nov 11, 2026$230.63$238.595$230.00$238.53944.34K
Nov 10, 2026$234.49$235.8519$231.13$234.111.2M
Nov 9, 2026$236.57$237.835$231.31$235.741.21M
Nov 6, 2026$234.00$236.67$231.95$235.301.72M
Nov 5, 2026$245.29$246.68$233.12$239.311.7M
Nov 4, 2026$235.39$242.215$234.106$240.512.26M
Nov 3, 2026$227.01$230.405$221.59$227.082.16M
Nov 2, 2026$231.27$233.76$227.731$232.941.6M
Oct 30, 2026$246.56$248.045$228.33$229.943.47M
Oct 29, 2026$253.57$254.27$249.60$252.831.45M
Oct 28, 2026$248.50$252.20$247.79$250.171.02M
Oct 27, 2026$250.33$251.765$247.70$250.80936.66K
Oct 26, 2026$251.48$254.99$249.44$253.201.07M
Oct 23, 2026$251.83$255.565$248.72$252.861.03M
Oct 22, 2026$245.41$253.62$244.18$253.061.73M

Latest RMD news

The latest Smart Investors Daily articles mentioning RMD.

RMD research

Overview

Company profile and research snapshot.

Company profile

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$296.00
Implied upside
—
Analysts
25
RMD recent ratings
DateFirmRatingTarget
Nov 2, 2026Canaccord GenuityHold—
Oct 30, 2026CitigroupNeutral—
Oct 30, 2026Wells FargoEqual-Weight—
Oct 30, 2026RBC CapitalOutperform—
Oct 30, 2026KeybancOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.